NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JAPIC ID: JapicCTI-111529

Registered date:

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedpsoriasis
Date of first enrollment
Target sample size
Countries of recruitment
Study typeINTERVENTIONAL
Intervention(s)Intervention name : AIN457 INN of the intervention : Secukinumab Dosage And administration of the intervention : Subcutaneous Injection Control intervention name : null

Outcome(s)

Primary OutcomeEfficacy of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis [ Time Frame: 12 weeks ]
Secondary OutcomeEfficacy of secukinumab in subjects with moderate to severe chronic plaque-type psoriasis [ Time Frame: 52 weeks ]

Key inclusion & exclusion criteria

Age minimum18
Age maximum
GenderBOTH
Include criteria-Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.
Exclude criteria-Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate). -Current drug-induced psoriasis. -Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.

Related Information

Contact

public contact
Name Novartis Pharma K.K. Novartis Direct
Address 0120-003-293
Telephone
E-mail
Affiliation
scientific contact
Name
Address
Telephone
E-mail
Affiliation